Hui Liu

发表

Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors.

Shaomeng Wang, Zhe-Sheng Chen, Guo‐Bo Li, 2021, Journal of medicinal chemistry.

Triazole-fused pyrimidines in target-based anticancer drug discovery.

Yichao Zheng, Xing Dai, Lei-Peng Xue, 2023, European journal of medicinal chemistry.

Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets.

M. Roberge, A. Baradaran‐Heravi, Z. Gan, 2021, ACS medicinal chemistry letters.

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.

A. Samatar, Sunny Abraham, S. Paliwal, 2021, Journal of medicinal chemistry.

New drug approvals for 2020: Synthesis and clinical applications.

Bin Yu, Shuo Yuan, Hui Liu, 2021, European journal of medicinal chemistry.

Oral treatment with Lactobacillus reuteri attenuates depressive-like behaviors and serotonin metabolism alterations induced by chronic social defeat stress.

Pei Jiang, Y. Qiao, Hui Liu, 2019, Journal of psychiatric research.

Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.

Yichao Zheng, Xing Dai, Xiao-Peng Xiong, 2023, European journal of medicinal chemistry.

Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.

Y. Liu, Li-Juan Zhao, Yichao Zheng, 2023, Journal of medicinal chemistry.

New drug approvals for 2021: Synthesis and clinical applications.

Sai-Yang Zhang, Hong-min Liu, Jian Song, 2022, European journal of medicinal chemistry.

A multiscale screening strategy for identification of novel xanthine oxidase inhibitors based on the pharmacological features of febuxostat analogues

Genyan Liu, Fengshou Wu, X. Ju, 2022, New Journal of Chemistry.